Chief Sales Officer of AI-Media Excited to Showcase Subtitling Innovation at Upcoming IBC Broadcast Tradeshow
BROOKLYN, N.Y., Sept. 13, 2023 (GLOBE NEWSWIRE) -- AI-Media, the leader in technology-driven live captioning & subtitling, transcription, and translation solutions, is excited to announce its presence at the IBC Show 2023, scheduled to take place from 15th – 18th September in Amsterdam, NE. The event promises to be a gathering of industry experts, thought leaders, and innovative companies in the broadcast and media technology sector.
As the global leader in captioning and subtitling for the broadcast industry, AI-Media is proud to be part of this influential event. Our Chief Sales Officer, James Ward, will lead our delegation and represent our commitment to excellence in delivering cutting-edge solutions to our clients and partners.
AI-Media’s Chief Sales Officer, James Ward said:
"We are delighted to participate at the IBC show once again. This tradeshow is an exceptional platform for us to showcase our latest innovations and demonstrate how we continue to push the boundaries of what's possible in the broadcast industry. We're excited to engage with industry leaders, customers, and partners, and to share our vision for the future of broadcasting."
AI-Media will be showcasing several key broadcast solutions at the event, the cornerstone of which is our AI-Powered live automatic captioning solution – LEXI. LEXI consistently delivers accuracy rates of over 98%, identifies speaker changes, uses AI to ensure captions don’t interrupt onscreen content and all at a fraction of the cost of human captions. This innovative tool is revolutionizing real-time captioning, providing a cost-effective solution that has been embraced by the world’s leading broadcasters. AI-Media will be conducting live demos at the booth to display this groundbreaking technology in action.
The recently launched AI-powered LEXI Captioning Tool Kit will also be featured at IBC2023, featuring six key solutions each designed to address different captioning needs. LEXI Tool Kit transforms content creation and captioning, offering complete end-to-end solutions for media companies, broadcasters, event producers, educational institutions, and content creators worldwide. Broadcasters can mix and match the Tool Kit components to suit their business needs, accessing solutions including captioning, translation, archiving & search and disaster recovery.
With IP video production at the forefront of innovation in the broadcasting landscape; broadcasters can look to AI-Media’s ALTA solution for their IP compatible closed captioning and subtitling encoding solution. ALTA supports global broadcast standards including SMPTE-2110, MPEG-TS inputs, and can output 2110-40, DVB subtitles, DVB TTML, DVB Teletext and SMPTE 2038. Deployable as a standalone virtual machine, a pre-packaged AMI or turnkey physical server, ALTA can fit into any production workflow. Along with effortlessly handling six languages per instance, ALTA also supports the insertion of advertising cues using SCTE-35 and SCTE-104. With ALTA, AI-Media is helping broadcasters elevate their IP video broadcasts to new heights of reach and accessibility. Also available at the booth will be our range of SDI Hardware Encoders, including our Encoder Pro (HD492) 1 RU caption encoder - now synonymous as the broadcast standard for SDI encoders.
We’re also excited to provide customers with an early look at our upgraded LEXI Translate solution, which is the next level of language accessibility within our LEXI Tool Kit. This soon to be released version boasts unmatched accuracy in real-time translation, allowing broadcasters to distribute content to a wider audience than ever before.
Join AI-Media at IBC 2023, September 15-18, RAI Amsterdam Convention Centre, Booth #5.C31. Attendees are encouraged to book a meeting with the AI-Media team to discover our range of end-to-end broadcast captioning solutions.
Founded in Australia in 2003, technology company AI-Media is a global leader in live and recorded captioning, transcription and translation solutions. The company helps the world’s leading broadcasters, enterprises and government agencies ensure high accuracy, secure and cost-effective captioning via its AI-powered LEXI automatic captioning solution. LEXI captions are delivered to millions of screens worldwide via AI-Media’s range of captioning encoders and its iCap Cloud Network – the world’s largest, most secure caption delivery network. Globally, AI-Media delivers over 8 million minutes of live and recorded media monthly. AI-Media trades on the Australian Stock Exchange (ASX:AIM). For more information, please visit AI-Media.tv.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/976356bd-2ae1-4f56-89ed-437f9da454a2To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 20234.12.2023 22:30:00 CET | Press release
Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2023 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights11/30/2023 96,431,770 Total gross of voting rights: 96,431,770 Total net* of voting rights: 96,186,256 * Net total = total number of voting rights attached to shares – shares without voting rights Attachment PDF Version
Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.4.12.2023 22:16:59 CET | Press release
Aggregate gross proceeds of approximately €50.9 million (equivalent to approximately $53.8 million) received by NANOBIOTIX has increased to approximately €55.5 million (equivalent to approximately $58.7 million) extending its runway into mid’ 2025 PARIS and CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announces today the closing of the previously announced subscription by Johnson & Johnson Innovation – JJDC, Inc. (“JJDC”) for 901,256 additional ordinary shares of the Company, in the form of restricted American Depositary Shares (“ADSs”), for an aggregate amount of $4.8 million, equivalent to €4.6 million1 (the “Remaining Placement Amount”, and the subscription transaction being the “Remaining Placement”), following the approval by the French Ministry of Economy of JJ
Inventiva announces the positive recommendation of the third DMC of the Phase III clinical trial with lanifibranor in patients with NASH4.12.2023 22:05:00 CET | Press release
The DMC recommended to continue the clinical trial without modification of the protocol, based on the pre-planned review of safety dataThe safety assessment was based on the review of safety data from more than 500 patients, including patients that have been treated with lanifibranor for more than 72 weeksThe DMC review remains consistent, confirming the good safety profile of lanifibranor Daix (France), Long Island City (New York, United States), December 4, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced the positive recommendation from the third meeting of the Data Monitoring Committee (DMC) to continue the NATiV3 Phase III clinical trial evaluating lanifibranor in patients with NASH without modification to the trial protocol. The DMC
Standard Lithium to Participate in December Investor Conferences4.12.2023 22:04:35 CET | Press release
VANCOUVER, British Columbia, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV:SLI) (NYSE American:SLI) (FRA:S5L), a leading near-commercial lithium development company, today announced its participation in the following virtual December investor conferences: Event:Deustche Bank 8th Annual Virtual Lithium Battery Supply Chain ConferenceDate:December 6, 2023Panel:US Based Lithium Supply, featuring Robert Mintak, CEO and Director of Standard Lithium, 7:45am – 8:15am PTEvent:Bank of America Securities Virtual 2023 Lithium and Battery Storage ConferenceDate:December 7, 2023Panel:Company Presentation, featuring Robert Mintak, CEO and Director of Standard Lithium, 7:45am – 8:30am PT Management will be hosting one-on-one meetings during the conferences. Interested investors should contact their Deutsche Bank or Bank of America representative or Standard Lithium Investor Relations at firstname.lastname@example.org. About Standard Lithium Ltd. St
Resignation of Director4.12.2023 20:00:33 CET | Press release
December 4, 2023 Announcement no. 19 Resignation of Director COPENHAGEN, DENMARK and BOSTON, MA, USA, December 4, 2023, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) announced today that Jan Leth Christensen has informed the Company that he has decided to resign from his position as a board member for BioPorto. The search for a successor with relevant expertise, including familiarity with public company practices in the Nordics, will be initiated and a new candidate is expected to be proposed in connection with the Company’s Annual General Meeting in 2024. “Jan has served on the board since the Annual General Meeting held in 2021. I would like to thank Jan for his important contributions to the board and collaboration in general” said John McDonough, BioPorto’s Chaiman of the Board of Directors. For investor inquiries, please contact: HC Andersen Capital, EU Investor Relations, +45 4529 0000, email@example.com Ashley R. Robinson, US Investor Relations,